Endothelin-1 receptor antagonists have been employed in patients with pulmonary hypertension to improve functional status and other indices ofpulmonary hypertension-related morbidity [73], further suggesting that ET-1 isan important mediator of pulmonary vascular dysregulation. This evidence concerns the gene EDN1 and pulmonary arterial hypertension.